Expired activity
Please go to the PowerPak
homepage and select a course.
Evolving Therapies for Advanced or Metastatic Hormone Receptor Positive (HR+) Breast Cancer: How Safety Profiles of CDK4/6 Inhibitors Affect Choice of First-Line Therapy – Case 1
INTRODUCTION
In 2018, about 40 820 women and 480 men will die from breast cancer, the vast majority of these patients will likely be associated with metastatic breast cancer (MBC).1-2 The majority of breast cancers express hormone receptors (HRs) for estrogen receptors (ER), and to a lesser extent, progesterone (PR).3-4 Tremendous progress has been made targeting hormone-responsive breast cancer through the manipulation of ER resulting in many endocrine-based therapy options for patients with HR-positive (HR+)/HER2-negative (HER2-) MBC. The recent introduction of cyclin-dependent kinase (CDK) 4/6 inhibitors has further expanded treatment options for these patients. Although MBC is not curable, it is now common for MBC to be treated as a more chronic condition, as patients transition from one therapy to the next.